pravastatin has been researched along with Atherogenesis in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (41.56) | 29.6817 |
| 2010's | 37 (48.05) | 24.3611 |
| 2020's | 8 (10.39) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, L; Pham, A; Polic, A; Thompson, JL | 1 |
| Liu, L; Su, R; Wen, T; Xiao, Z; Xie, Y; Xu, J; Zhang, M; Zhu, L | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
| Jia, Z; Li, H; Li, M; Li, Q; Liang, X; Su, D; Xuan, W | 1 |
| Avihingsanon, A; Bautista-Arredondo, S; Bendavid, E; Boettiger, DC; Chaiwarith, R; Chattranukulchai, P; Kahn, JG; Khusuwan, S; Kiertiburanakul, S; Law, MG; Newall, AT; Phillips, A; Ross, J | 1 |
| Chen, Y; Hu, L; Jia, J; Liu, X; Luo, X; Ou, Y; Shen, W; Shi, H; Sun, S; Zhang, H; Zhou, G | 1 |
| Andia, ME; Botnar, RM; Lavin Plaza, B; Lorrio, S; Phinikaridou, A; Potter, M; Rashid, I | 1 |
| Abeydeera, D; Demer, LL; Fong, F; Iriana, S; Lu, M; Patel, NR; Qiao, R; Tintut, Y; Xian, JZ | 1 |
| Heo, TH; Park, KY | 2 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Li, Q; Xiao, S; Zhang, X | 1 |
| Gao, JH; Lu, JL; Wang, HM | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 2 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Daida, H; Kitagawa, Y; Matsushita, Y; Sugihara, M; Teramoto, T | 1 |
| Ara, N; Iuchi, A; Miyoshi, H; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Díaz Rodríguez, Á | 1 |
| Mantilla, T | 1 |
| Hernández Mijares, A | 1 |
| González, DF | 1 |
| Arai, M; Kako, N; Kawasaki, M; Minatoguchi, S; Miwa, H; Nagaya, M; Noda, T; Onishi, N; Ono, K; Saeki, M; Sato, N; Tanaka, R; Watanabe, S; Watanabe, T | 1 |
| Braamskamp, MJ; Hutten, BA; Wiegman, A | 1 |
| Ángeles-Garay, U; Carrillo-González, AL; Hernández, C; Jara, L; Medina, G; Olvera-Acevedo, A; Peralta-Amaro, AL; Vera-Lastra, OL | 1 |
| Liu, J; Lu, P; Pang, X | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Calderón-Aranda, E; Cruz-Dominguez, MP; Jara, LJ; Medina, G; Méndez-Flores, S; Vera-Lastra, O | 1 |
| Heo, TH; Jun, HS; Kwak, MK; Oh, E; Park, KY | 1 |
| Roever, L | 1 |
| Baranska, M; Chlopicki, S; Czyzynska-Cichon, I; Drahun, A; Franczyk-Zarow, M; Gasior-Glogowska, M; Jasztal, A; Kostogrys, RB; Kus, E; Manterys, A; Wrobel, TP | 1 |
| Chae, A; Choi, SH; DeMaria, AN; Messig, M; Miller, E; Nissen, SE; Ntanios, F; Tsimikas, S; Witztum, JL | 1 |
| del Sol, AI; Nanayakkara, PW | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Gao, PJ; Sun, BG; Zhou, XX | 1 |
| Fraser, H; Lusis, AJ; Shaposhnik, Z; Trias, J; Wang, X | 1 |
| Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozue, T; Sato, A; Sozu, T; Takeyama, Y; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Anantharamaiah, GM; Fogelman, AM; Hama, S; Hough, G; Lehrer, RI; Navab, M; Palgunachari, MN; Ruchala, P; Waring, AJ | 1 |
| David, S; Fliser, D; Haller, H; Kielstein, JT; Kümpers, P; Lukasz, A | 1 |
| Koh, KK | 1 |
| David, S; Fliser, D; Haller, H; Kielstein, JT; Lorenzen, JM; Neunhöffer, H | 1 |
| Hennekens, C | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Campos, H; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Louie, JZ; Sabatine, MS; Sacks, FM; Shiffman, D | 1 |
| Arruda, AP; Breder, I; Coope, A; de Oliveira, HC; Dorighello, Gde G; Milanski, M; Razolli, D; Velloso, LA | 1 |
| Major, A; Mendez-Fernandez, Y | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Ishibashi, T | 1 |
| Daida, H; Kitagawa, Y; Teramoto, T | 1 |
| Dhiman, MK; Petkar, K; Sawant, K; Yedurkar, P | 1 |
| Huang, C; Huang, Z; Jiang, H; Wu, G; Xie, Q; Xu, L | 1 |
| Anantharamaiah, GM; Fogelman, AM; Frank, JS; Garber, DW; Hama, S; Handattu, S; Hough, G; Navab, M; Reddy, ST | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Frazier, OH; Radovancevic, B; Radovancevic, R; Stojanovic, I; Thomas, CD; Vrtovec, B; Yazdanbakhsh, AP | 1 |
| Inaba, T; Kato, M; Kitayama, K; Koike, H; Mizuno, M; Sada, T | 1 |
| Field, KM | 1 |
| Cannon, CP; Ray, KK | 1 |
| Kametsu, Y; Kitagawa, Y; Sekiyama, S; Takagi, S | 1 |
| Fukushima, H; Hirai, T; Honda, O; Horibata, Y; Koga, H; Kugiyama, K; Ogawa, H; Sakamoto, T; Sugiyama, S; Watanabe, K; Yamashita, Y; Yoshimura, M | 1 |
| de Paula-Coelho, VN; Junqueira, LF; Karnib, SR; Muniz-Junqueira, MI | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Feng, JH; Kang, MF; Li, YQ; Ma, LP; Nie, DN; Wu, YD; Xie, SF; Xu, LZ; Yin, SM | 1 |
| Hayashi, J; Maeda, S; Ohnishi, H; Okada, K; Sawayama, Y | 1 |
| Filella, X; Franquesa, J; Marcos, JM; Molina, R; Morales, C; Salinas, R; Trapé, J | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Adams, V; Erbs, S; Goettsch, W; Hambrecht, R; Holtz, J; Krekler, M; Kuss, O; Lenk, K; Mohr, FW; Morawietz, H; Schubert, A; Schuler, G | 1 |
| Belzunce, M; Orbe, J; Páramo, JA; Rodríguez, JA; Roncal, C | 1 |
| Dever, G; Kennedy, S; Monopoli, A; Rush, C; Spickett, CM; Tennant, G; Wainwright, CL | 1 |
| Arakawa, E; Hasegawa, K; Ina, Y; Matsubara, M; Takada, C; Takayama, M; Yao, K | 1 |
| Angri, V; Calabrò, P; Chiariello, M; Cirillo, P; De Rosa, S; Fiorentino, I; Gargiulo, A; Musto D'Amore, S; Pacileo, M; Petrillo, G; Prevete, N; Sasso, L; Ucci, G | 1 |
| Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F | 1 |
| Havekes, LM; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM; van der Hoorn, JW | 1 |
| Benson, R; Dever, GJ; Kennedy, S; Spickett, CM; Wainwright, CL | 1 |
12 review(s) available for pravastatin and Atherogenesis
| Article | Year |
|---|---|
Statins in Pregnancy: Can We Justify Early Treatment of Reproductive Aged Women?
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lactation; Pravastatin; Pregnancy | 2022 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
[Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
Early initiation of statin treatment in children with familial hypercholesterolaemia.
Topics: Atherosclerosis; Child; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pravastatin; Treatment Outcome | 2015 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Pravastatin: an evidence-based statin?
Topics: Atherosclerosis; Cardiovascular Diseases; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Treatment Outcome | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2007 |
[Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Monomeric GTP-Binding Proteins; Plaque, Atherosclerotic; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention | 2011 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Optimal goals for statin use in patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Treatment Outcome | 2005 |
21 trial(s) available for pravastatin and Atherogenesis
| Article | Year |
|---|---|
Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipids; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 2023 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
Topics: Aged; Atherosclerosis; Biomarkers; Coronary Artery Disease; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Japan; Male; Middle Aged; Pravastatin; Prospective Studies | 2014 |
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Influence of comorbid cardiovascular risk factors on left atrial-left ventricular interaction in asymptomatic patients: clinical application of two-dimensional speckle-tracking echocardiography.
Topics: Aged; Atherosclerosis; Atrial Function, Left; Carotid Intima-Media Thickness; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study).
Topics: Aged; Anti-Inflammatory Agents; Atherosclerosis; Carotid Arteries; Echocardiography, Transesophageal; Female; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Pravastatin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Systems Integration; Thoracic Arteries; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Effect of pravastatine plus ezetimibe on carotid intima media thickness in patients with lupus erythematosus].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Lupus Erythematosus, Systemic; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2015 |
Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): rationale and design.
Topics: Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pravastatin; Prospective Studies; Quinolines; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
Topics: Adult; Aged; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Male; Middle Aged; Pravastatin; Prospective Studies; Tetrazoles; Vasculitis | 2009 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial.
Topics: Alleles; Atherosclerosis; Cholesterol; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Myocardial Infarction; Polymerase Chain Reaction; Polymorphism, Genetic; Pravastatin; Prevalence; Prospective Studies; Risk Factors; Secondary Prevention; Survival Rate; Treatment Outcome; United States | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Pravastatin; Prospective Studies; Triglycerides; Ultrasonography, Interventional | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Pravastatin; Probucol; Risk; Treatment Outcome | 2006 |
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Elective Surgical Procedures; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Irbesartan; Mammary Arteries; Membrane Glycoproteins; Muscle, Smooth, Vascular; NADPH Oxidase 2; NADPH Oxidases; Natriuretic Peptide, C-Type; Nitric Oxide Synthase Type III; Oxidative Stress; Polymerase Chain Reaction; Pravastatin; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Scavenger Receptors, Class E; Tetrazoles | 2006 |
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
44 other study(ies) available for pravastatin and Atherogenesis
| Article | Year |
|---|---|
HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation.
Topics: Apoptosis; Atherosclerosis; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Transcription Factors; Lipoproteins, LDL; Pravastatin; Proteolysis; Scavenger Receptors, Class E; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Topics: Adult; Atherosclerosis; Cost-Benefit Analysis; Drug Costs; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Quinolines; Thailand | 2020 |
Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C
Topics: Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin | 2020 |
Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Brachiocephalic Trunk; Collagen; Disease Models, Animal; Disease Progression; Inflammation Mediators; Interleukin-6; Lipid Metabolism; Male; Mice, Knockout, ApoE; Minocycline; Necrosis; Plaque, Atherosclerotic; Pravastatin; Time Factors | 2020 |
Statin Effects on Vascular Calcification: Microarchitectural Changes in Aortic Calcium Deposits in Aged Hyperlipidemic Mice.
Topics: Age Factors; Animals; Aorta; Aortic Diseases; Atherosclerosis; Calcium; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Pravastatin; Rupture, Spontaneous; Time Factors; Vascular Calcification | 2021 |
Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.
Topics: Aging; Animals; Atherosclerosis; Cholesterol, Dietary; Cytokines; Diet, High-Fat; Drug Therapy, Combination; Etanercept; Fibrinolytic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pravastatin; Receptors, LDL; Succinates; Tumor Necrosis Factor-alpha | 2017 |
Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice.
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cholesterol; Disease Models, Animal; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Pravastatin | 2018 |
Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Hyperlipidemias; Interleukin-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pravastatin; Triggering Receptor Expressed on Myeloid Cells-1; Tumor Necrosis Factor-alpha | 2018 |
Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cell Adhesion Molecules; Cholesterol, Dietary; Cilostazol; Cytokines; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pravastatin; Receptors, LDL | 2018 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
[The fixed combination of pravastatin and fenofibrate: what can it provide?].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Pravastatin; Risk Factors | 2014 |
[Achievement of therapeutic objectives].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Pravastatin; Risk Factors | 2014 |
[Treatment of older patients with dyslipidemia].
Topics: Age Factors; Aged; Atherosclerosis; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Pravastatin; Quality of Life | 2014 |
Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-α and iNOS in vascular smooth muscle cells.
Topics: Animals; Atherosclerosis; Cell Line; Dose-Response Relationship, Drug; Fibrin Fibrinogen Degradation Products; Fibrinogen; Inflammation; Interleukin-6; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type II; Pravastatin; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2015 |
Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Brachial Artery; C-Reactive Protein; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Pravastatin; Ultrasonography; Vasodilation | 2016 |
Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
Topics: Animals; Atherosclerosis; Cell Proliferation; Cytokines; Drug Synergism; Gene Expression Regulation; Gene Knockout Techniques; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Myocytes, Smooth Muscle; Plaque, Atherosclerotic; Pravastatin; Receptors, LDL; Succinates | 2016 |
Pitavastatin versus Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias.
Topics: Atherosclerosis; Cholesterol; Dyslipidemias; Humans; Pravastatin; Triglycerides | 2016 |
Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Brachiocephalic Trunk; Female; Mice; Mice, Knockout; Pravastatin; Receptors, LDL; Treatment Outcome | 2017 |
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Coronary Angiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Male; Malondialdehyde; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2008 |
Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Down-Regulation; Drug Evaluation, Preclinical; Gene Expression Regulation; Hypolipidemic Agents; Interferon Regulatory Factor-1; Interferon-gamma; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pravastatin; STAT1 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2009 |
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Topics: Acetates; Animals; Apolipoproteins E; Aryldialkylphosphatase; Atherosclerosis; Drug Synergism; Enzyme Inhibitors; Indoles; Keto Acids; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phospholipases A2, Secretory; Pravastatin; Prodrugs | 2009 |
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Biological Availability; Female; Humans; Inflammation; Lipoproteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Mimicry; Niclosamide; Peptides; Pravastatin; Protein Structure, Secondary | 2009 |
Combination treatment to prevent atherosclerosis.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Drug Therapy, Combination; Dyslipidemias; Humans; Hypertension; Pravastatin | 2009 |
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Male; Middle Aged; Osteopontin; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Tetrazoles | 2010 |
Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosis.
Topics: Animals; Antigens, Differentiation; Atherosclerosis; Cell Line; Disease Models, Animal; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Fatty Acids; Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Phosphorylation; Pravastatin; Receptors, LDL; Regulatory Factor X Transcription Factors; Simvastatin; Stress, Physiological; Transcription Factors | 2010 |
Sizing up stability: combination therapy with Apo-AI peptide mimetics and statins in systemic lupus erythematosus-mediated atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Atherosclerosis; Drug Therapy, Combination; Humans; Lupus Erythematosus, Systemic; Mice; Peptides; Plaque, Atherosclerotic; Pravastatin | 2010 |
APPROACH-J study: design, rationale, and baseline data of the affirmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study.
Topics: Adult; Atherosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin; Primary Prevention | 2011 |
Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis.
Topics: Acrylates; Administration, Buccal; Animals; Area Under Curve; Atherosclerosis; Biological Availability; Drug Delivery Systems; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypromellose Derivatives; Male; Methylcellulose; Mouth Mucosa; Pravastatin; Rabbits; Solubility | 2013 |
Pravastatin inhibits plaque rupture and subsequent thrombus formation in atherosclerotic rabbits with hyperlipidemia.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Aorta; Aorta, Abdominal; Atherosclerosis; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Histamine; Hyperlipidemias; Male; Plaque, Atherosclerotic; Pravastatin; Rabbits; Thrombosis; Thromboxane B2; Triglycerides; Viper Venoms | 2013 |
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
Topics: Age Factors; Animal Feed; Animals; Anti-Inflammatory Agents; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Chemotaxis, Leukocyte; Cholesterol, HDL; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Macaca fascicularis; Male; Mice; Mice, Mutant Strains; Monocytes; Pravastatin | 2005 |
Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Middle Aged; Pravastatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cholesterol; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Immunohistochemistry; Macrophages; Olmesartan Medoxomil; Pravastatin; Rabbits; Tetrazoles; Tunica Intima | 2005 |
Increase in plasma malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Carotid Arteries; Cerebral Infarction; Cholesterol, LDL; Female; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Pravastatin; Statistics as Topic; Ultrasonography, Doppler | 2005 |
Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals.
Topics: Adult; Atherosclerosis; Female; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Middle Aged; Monocytes; Phagocytosis; Pravastatin; Saccharomyces cerevisiae | 2006 |
[The effects of pravastatin on platelet-derived nitric oxide system in rabbits].
Topics: Animals; Atherosclerosis; Blood Platelets; Disease Models, Animal; Male; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Rabbits; RNA, Messenger | 2005 |
Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Inflammation Mediators; Male; Middle Aged; Neovascularization, Pathologic; Pravastatin; Triglycerides; Vascular Endothelial Growth Factor A | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin.
Topics: Analysis of Variance; Atherosclerosis; Cells, Cultured; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Plasminogen Activator Inhibitor 1; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Umbilical Veins | 2006 |
The nitric oxide-donating pravastatin derivative, NCX 6550 [(1S-[1alpha(betaS*, deltaS*), 2alpha, 6alpha, 8beta-(R*), 8a alpha]]-1,2,6,7,8,8a-Hexahydro-beta, delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic acid 4-(nitrooxy)but
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Adhesion; Chemokine CCL2; Cholesterol; Endothelium, Vascular; Female; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Nitrates; Nitric Oxide Donors; Pravastatin; Reactive Oxygen Species; Spleen; Thrombin | 2007 |
Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Calcium Channel Blockers; Cholesterol; Dihydropyridines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperplasia; Male; Pravastatin; Rabbits; RNA, Messenger; Scavenger Receptors, Class E; Time Factors; Tunica Intima; Up-Regulation; Vascular Cell Adhesion Molecule-1; Vasodilation | 2007 |
HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; NF-kappa B; Nicotine; Nicotinic Agonists; Pravastatin; Protein Kinase C; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Smoking; Superoxide Dismutase; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoprotein E3; Atherosclerosis; Blood Pressure; Collagen; Diet, Atherogenic; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation; Lipids; Macrophages; Mice; Mice, Transgenic; Monocytes; Muscle, Smooth, Vascular; Pravastatin; Recombinant Proteins; Serum Amyloid A Protein; T-Lymphocytes; Tetrazoles | 2007 |
Phospholipid chlorohydrin induces leukocyte adhesion to ApoE-/- mouse arteries via upregulation of P-selectin.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteries; Atherosclerosis; Cell Adhesion; Chlorohydrins; Hypochlorous Acid; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Lipoproteins, LDL; Mice; Mice, Knockout; Nitrates; P-Selectin; Phosphatidylcholines; Phospholipids; Pravastatin; Reactive Oxygen Species; Up-Regulation | 2008 |